Opportunities for Healthy Volunteers
Contribute to medical research by participating in studies designed for healthy participants in your selected area.
↓
Matched clinical trials
Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment
Not recruiting
Investigated Diseases:Investigated Drugs:
+3
Study on TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Ineligible for or Refusing Platinum-Based Chemotherapy
Not recruiting
Investigated Diseases:Investigated Drugs:
Study of erdafitinib versus chemotherapy (gemcitabine or mitomycin) for patients with high-risk non-muscle-invasive bladder cancer with FGFR mutations who failed BCG therapy
Not recruiting
Investigated Diseases:Investigated Drugs:
Study on TAR-200 and Cetrelimab for High-Risk Bladder Cancer Patients Not Responding to BCG and Unable or Unwilling to Have Surgery
Not recruiting
Investigated Diseases:Investigated Drugs:
+2
Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy
Not recruiting
Investigated Diseases:Investigated Drugs:
+1
Study of TAR-200 and Cetrelimab for Patients with Muscle-Invasive Bladder Cancer Not Undergoing Radical Cystectomy
Not recruiting
Investigated Drugs:
+4
Study on Enfortumab Vedotin and Pembrolizumab for Patients with Advanced Urothelial Cancer
Not recruiting
Investigated Diseases:Investigated Drugs:
Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer
Not recruiting
Investigated Drugs:
+4
